UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | K | L | M | N | O | P | Q | R | S | T | U | V | W | Y
Number of items: 72.

A

Arkenau, HT; (2009) Capecitabine/oxaliplatin results in outcome similar to infusional 5 FU/leucovorin/oxaliplatin in MCRC: Results of a meta-analysis. American Journal of Hematology/ Oncology , 8 (5)

B

BBC, NO; (2009) Thalidomide lung cancer 'failure'. UNSPECIFIED

Black, E; Glasspool, DW; Grando, MA; Patkar, V; Fox, J; (2009) Goal-Based Decisions for Dynamic Planning. In: Combi, C and Shahar, Y and AbuHanna, A, (eds.) ARTIFICIAL INTELLIGENCE IN MEDICINE, PROCEEDINGS. (pp. 96 - 100). SPRINGER-VERLAG BERLIN

Bradshaw, TD; Stevens, MFG; Calvert, H; Plummer, ER; (2009) Preliminary clinical experiences of Phortress: Putative role for c-MET inhibition in antitumor activity. In: AMER ASSOC CANCER RESEARCH

Brown, ACN; Hallouane, D; Mawby, WJ; Karet, FE; Saleem, MA; Howie, AJ; Toye, AM; (2009) RhCG is the major putative ammonia transporter expressed in the human kidney, and RhBG is not expressed at detectable levels. Am J Physiol Renal Physiol , 296 (6) F1279-F1290. 10.1152/ajprenal.00013.2009.

C

Carle, D; Bielack, S; Sydes, M; Butterfass-Bahloul, T; Calaminus, G; Jovic, G; Marina, N; ... Bernstein, M; + view all (2009) The European and American Osteosarcoma Study Group protocol EURAMOS 1: Successful transatlantic cooperation in osteosarcoma. In:

D

Dancey, G; Violet, J; Malaroda, A; Green, AJ; Sharma, SK; Francis, R; Othman, S; ... McNamara, C; + view all (2009) A Phase I Clinical Trial of CHT-25 a I-131-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. CLIN CANCER RES , 15 (24) 7701 - 7710. 10.1158/1078-0432.CCR-09-1421.

Desai, K; Bhattacharya, S; Srirajaskanthan, R; Morgan-Rowe, L; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. In: (Proceedings) 45th Annual Meeting of the American-Society-of-Clinical-Oncology. AMER SOC CLINICAL ONCOLOGY

Desai, K; Bhattacharya, S; Srirajaskanthan, R; Morgan-Rowe, L; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. J Clin Oncol , 27 (15_suppl) , Article e15650.

de Bono, JS; Brunetto, A; Kristeleit, RS; Mais, A; Hauns, B; Hentsch, B; (2009) Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. European journal of cancer , 7 (2) p. 137.

E

Ella, W; Short, SC; (2009) Using retinoids to increase radio-iodine uptake in thyroid cancer: role as potential redifferentiation agents. In: The handbook on iodine. Elsevier

Essafi, A; Gomes, AR; Pomeranz, KM; Zwolinska, AK; Varshochi, R; McGovern, UB; Lam, EW-F; (2009) Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt. Methods Mol Biol , 462 pp. 201-211. 10.1007/978-1-60327-115-8_13.

F

Fern, L; Ashton, J; Broonan, K; Irving, C; Millington, H; Starkey, C; Wright, D; (2009) Involving young people with cancer in research. The National Cancer Research Institute’s Teeange and Young Adult Core Consumer Group – a new and evolving model. In:

G

George, S; Lal, R; Camidge, DR; Arkenau, H; Chick, J; Poondru, S; Yap, TA; ... Scurr, M; + view all (2009) Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Gibson, F; Aldiss, S; Taylor, RM; Maguire, R; Kearney, N; (2009) Involving health professionals in the development of an advanced symptom management system for young people: The ASyMS<sup>©</sup>-YG study. European Journal of Oncology Nursing , 13 (3) pp. 187-192. 10.1016/j.ejon.2009.03.004.

Gibson, F; Pearce, S; Eden, T; Glaser, A; Hooker, L; Whelan, J; Kelly, D; (2009) CANCER IN YOUNG PEOPLE: A NARRATIVE STUDY TO EXPLORE THEIR EXPERIENCE FROM FIRST SYMPTOMS TO THE DIAGNOSIS OF CANCER. In: PEDIATR BLOOD CANCER. (pp. 751 - 751). WILEY-LISS

H

Hall, JRAS; SC, ; (2009) Management of Glioblastoma Multiforme in HIV patients: a case series and review of published studies. Clinical Oncology

Harland, SJ; Welch, R; Huddart, R; Stenning, S; Pollock, P; Gabe, R; (2009) On the necessity for postchemotherapy surgery for residual abdominal masses in metastatic nonseminomatous germ cell tumors (NSGCT) of testis. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Hatton, C; Peniket, A; Tusold, A; Collins, G; Joyner, M; Lee, R; Mouncey, P; (2009) Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma. In: (Proceedings) 49th Annual Scientific Meeting/British Society for Haematology, Brighton.. (pp. 13-). British Journal of Haematology

Hewish, M; Miller, R; Forster, MD; Smith, IE; (2009) Severe synergistic toxicity from docetaxel in a patient treated concurrently with protease inhibitors as part of HIV-exposure prophylaxis: a case report. Journal of Medical Case Reports , 3 8866-.

Hochhauser, D; Meyer T, L; P, S; V J, C; M, B; R H, W; J, C; ... D, ; + view all (2009) Phase I study of the DNA minor groove binding pyrrolobenzodiazepine dimer (SJG 136) administered every 21 days in patients with advanced solid tumours. Clinical Cancer Research , 15 (6) pp. 2140-2147.

Howard, PW; Chen, Z; Gregson, SJ; Masterson, L; Tiberghien, AC; Cooper, N; Fang, M; ... Thurston, DE; + view all (2009) Synthesis of a novel C2/C2?-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. Biorganic and Medicinal Chemistry Letters , 19 (22) pp. 6463-6466. 10.1016/j.bmcl.2009.09.012.

K

Kristeleit, R; Calvert, H; Arkenau, H; Olmos, D; Adam, J; Plummer, ER; Lock, V; ... Judson, I; + view all (2009) A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. J Clin Oncol , 27 (15_suppl) 2566-.

Kristeleit, R; O'Brien, M; (2009) Cardiotoxicity from cytotoxics in the 21st century. British Journal of Cardiology , 16 (2) pp. 60-62.

Kristeleit, RS; Calvert, H; Arkenau, H; Olmos, D; Adam, J; Plummer, ER; Lock, V; ... Judson, I; + view all (2009) A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. Journal of Clinical Oncology , 27 (15S)

Kulkarni, AA; Kingsbury, SR; Tudzarova, S; Hong, HK; Loddo, M; Rashid, M; Rodriguez-Acebes, S; ... Williams, GH; + view all (2009) Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma. CLIN CANCER RES , 15 (7) 2417 - 2425. 10.1158/1078-0432.CCR-08-1276.

L

Lee, SM; Hackshaw, A; (2009) Correspondence. Response: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomised, double-blind, placebo-controlled trial. Journal of the National Cancer Institute

Lee, SM; Woll, PJ; Rudd, R; Ferry, D; O'Brien, M; Middleton, G; Spiro, S; ... Hackshaw, A; + view all (2009) Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst , 101 (15) pp. 1049-1057. 10.1093/jnci/djp200. Green open access

Leitner, S; Sweeney, K; Oberg, D; Davies, D; Miranda, E; Lemoine, NR; Hallden, G; (2009) Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo. Clinical Cancer Research , 15 (5) pp. 1730-1740. 10.1158/1078-0432.CCR-08-2008.

Liu, J; Lu, X; Drummond, C; Hutton, C; Jackson, J; Bennaceur, K; Newell, D; ... Lunec, J; + view all (2009) Mechanisms of cellular resistance to the growth inhibitory and cytotoxic effects of MDM2-p53 binding antagonists. In: AMER ASSOC CANCER RESEARCH

Loddo, M; Kingsbur, SR; Rashid, M; Proctor, I; Holt, C; Young, J; El Sheikh, S; ... Williams, GH; + view all (2009) Cell cycle phase progression analysis identifies unique replication phenotypes of major prognostic and predictive significance in cancer. In: CANCER RESEARCH. (pp. 320S - 320S). AMER ASSOC CANCER RESEARCH

Lolkema, MP; Harrington, K; Evans, J; Arkenau, HT; Roxburgh, P; Morrison, R; Roulstone, V; ... de Bono, J; + view all (2009) A phase-I study of the combination of intravenous reovirus (REOLYSIN (R)) and gemcitabine in patients with advanced cancer. In: (Proceedings) 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology. (pp. p. 131). PERGAMON-ELSEVIER SCIENCE LTD

Lowe, HL; Sharma, SK; Bagshawe, KD; Chester, KA; (2009) Antibody directed enzyme prodrug therapy (ADEPT). In: Recombinant Antibodies for Immunotherapy. (pp. 336-349).

M

Mahendran, AO; Elvey, M; Mahendran, M; Howie, AJ; Dupont, P; Veitch, PS; (2009) EARLY RENAL TRANSPLANT PROTOCOL BIOPSIES DIRECTLY INFLUENCE PATIENT MANAGEMENT. TRANSPLANT INTERNATIONAL , 22 p. 16.

Mahendran, AO; Haroon, S; Dupont, PJ; Howie, A; Veitch, PS; (2009) AN INCREMENTAL INCREASE IN CHRONIC ALLOGRAFT DAMAGE DETECTED ON PROTOCOL BIOPSIES DURING THE FIRST YEAR POST-TRANSPLANTATION. TRANSPL INT , 22 260 - 260.

Makrogianneli, K; Carlin, LM; Keppler, MD; Matthews, DR; Ofo, E; Coolen, A; Ameer-Beg, SM; ... Ng, T; + view all (2009) Integrating receptor signal inputs that influence small Rho GTPase activation dynamics at the immunological synapse. Mol Cell Biol , 29 (11) pp. 2997-3006. 10.1128/MCB.01008-08.

Marelli, L; Shusang, V; Buscombe, JR; Cholongitas, E; Stigliano, R; Davies, N; Tibballs, J; ... Burroughs, AK; + view all (2009) Transarterial Injection of I-131-Lipiodol, Compared with Chemoembolization, in the Treatment of Unresectable Hepatocellular Cancer. JOURNAL OF NUCLEAR MEDICINE , 50 (6) pp. 871-877. 10.2967/jnumed.108.060558.

McGovern, UB; Francis, RE; Peck, B; Guest, SK; Wang, J; Myatt, SS; Krol, J; ... Lam, EW-F; + view all (2009) Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther , 8 (3) pp. 582-591. 10.1158/1535-7163.MCT-08-0805.

McGovern, UB; Stebbing, J; (2009) Receptor-based predictors of response in breast cancer. [Editorial comment]. Future Oncology , 5 (3) 283 - 286. 10.2217/fon.09.1. Green open access
file

Meyer, T; (2009) Interventional Radiological Treatment of Liver Tumours. British Journal of Cancer , 100 p. 1975.

N

Ng, T; Boguslavsky, SK; Tarcic, G; Wakim, J; Kiuchi, T; Liu, A; Reinitz, F; (2009) An Unbiased Screen Identifies DEP-1 Tumor Suppressor as a Phosphatase Controlling EGFR Endocytosis. Current Biology , 19 (21) pp. 1788-1798. 10.1016/j.cub.2009.09.048.

O

Observer, ; (2009) Smoking is a childhood addiction. Protect our children-vote to put tobacco out of sight.

Olmos, D; Brunetto, A; Ang, J; Tan, D; Sandhu, S; Kristeleit, R; Lolkelma, M; ... Kaye, S; + view all (2009) 1257 Retrospective analysis of unplanned hospital admissions: an early surrogate indicator of patient (pt) attrition in phase-I trials. European Journal of Cancer Supplements , 7 (2) pp. 137-138. 10.1016/S1359-6349(09)70469-0.

Olmos, D; Brunetto, A; Ang, J; Tan, D; Sandhu, S; Kristeleit, R; Lolkelma, M; ... Kaye, S; + view all (2009) Retrospective analysis of unplanned hospital admissions: an early surrogate indicator of patient (pt) attrition in phase-I trials. In: (Proceedings) 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology. (pp. pp. 137-138). PERGAMON-ELSEVIER SCIENCE LTD

P

Pacey, SC; Wilson, R; Walton, M; Eatock, M; Zetterlund, A; Arkenau, H; Beecham, R; ... Judson, I; + view all (2009) A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Pankhurst, T; Lepenies, J; Nightingale, P; Howie, AJ; Adu, D; Harper, L; (2009) Vasculitic IgA nephropathy: prognosis and outcome. Nephron Clin Pract , 112 (1) c16-c24. 10.1159/000210570.

Paulussen, M; Craft, A; Lewis, I; Hackshaw, A; Douglas, C; Whelan, J; Jurgens, HFDEICESSSG; (2009) Zwei randomisierte Ewing Sarkom Studien Schweizer Krebsbulletin. Bulletin suisse du cancer , 29 (2) pp. 128-134.

Pearce, S; Gibson, F; Eden, T; Glaser, A; Hooker, L; Whelan, J; Kelly, D; (2009) The experiences of young people from first symptoms to the diagnosis of cancer: a narrative study. In: (pp. 234-).

Pearce, S; Gibson, F; Eden, TE; Glaser, A; Hooker, L; Whelan, J; Kelly, D; (2009) A narrative study of the experiences of young people from first symptoms to the diagnosis of cancer. In:

Plummer, R; Coronado, C; Massard, C; Calvert, AH; Margetts, J; Bahleda, R; Prados, R; ... Soria, J-C; + view all (2009) Phase I, open-label, dose-escalating clinical and pharmacokinetic study of PM00104 administered weekly resting every fourth week, intravenously, over 1 hour to patients with advanced malignant solid tumors or lymphoma. In: AMER ASSOC CANCER RESEARCH

Plummer, R; Hayward, L; Lorigan, P; Soriano, V; Moiseyenko, V; Szyldergemajn, S; Prados, R; ... Calvert, H; + view all (2009) Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). J Clin Oncol , 27 (15_suppl) 9059-.

Q

Quinn, AE; Pinkney, M; Piggott, NH; Calvert, H; Milton, ID; Lunec, J; (2009) A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues. HYBRIDOMA , 28 (6) 415 - 421. 10.1089/hyb.2009.0040.

R

Razak, ARA; Nutt, JE; O'Toole, K; Black, F; Plummer, ER; Calvert, AH; Lunec, J; (2009) Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis. Lung Cancer , 63 82-.

S

Short, SC; (2009) Re-irradiation of brain tumours-evidence, indications and limitations. In: (pp. pp. 410-411).

Singh, KJDAL; O'Hare, MJ; Pizzey, A; Appasammy, M; Stein, RC; Muttukrishna, S; (2009) Ovarian Granulosa Cells Have Varying Sensitivity to Different Cytotoxic Drugs Used To Treat Young Breast Cancer Patients. In: (Proceedings) 56th Annual Meeting of the Society-for-Gynecologic-Investigation. (pp. 151A-151A). SAGE PUBLICATIONS INC

Srirajaskanthan, R; Desai, K; Jayaratnam, A; Carras, E; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Uncommon sites for metastasis of neuroendocrine tumor in adults. In: (Proceedings) 45th Annual Meeting of the American-Society-of-Clinical-Oncology. AMER SOC CLINICAL ONCOLOGY

Srirajaskanthan, R; Desai, K; Jayaratnam, A; Carras, E; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Uncommon sites for metastasis of neuroendocrine tumor in adults. J Clin Oncol , 27 (15_suppl) , Article e15683.

Srirajaskanthan, R; McStay, M; Toumpanakis, C; Meyer, T; Caplin, ME; (2009) Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology , 89 (1) pp. 48-55. 10.1159/000151222.

Stavridi, F; Kristeleit, R; Forster, M; Ang, J-E; Rudman, S; Uttenreuther-Fischer, M; Pemberton, K; ... Spicer, J; + view all (2009) Activity of BIBW 2992, an oral irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer. In: (pp. S444-S444). LIPPINCOTT WILLIAMS & WILKINS

Stephens, HA; Cox, S; Fernando, R; Howie, AJ; Harber, M; Little, A-M; (2009) MICA ANTIBODIES ASSOCIATE WITH BIOPSY-PROVEN CELLULAR REJECTION IN RENAL TRANSPLANT RECIPIENTS. TRANSPLANT INTERNATIONAL , 22 p. 69.

T

Toumpanakis, C; Quigley, A; Srirajaskanthan, R; Marelli, L; Singhrao, T; Meyer, T; Buscombe, J; (2009) 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. In: (Proceedings) 45th Annual Meeting of the American-Society-of-Clinical-Oncology. AMER SOC CLINICAL ONCOLOGY

Toumpanakis, C; Quigley, A; Srirajaskanthan, R; Marelli, L; Singhrao, T; Meyer, T; Buscombe, J; (2009) 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. J Clin Oncol , 27 (15_suppl) 4594-.

U

UCL, SOLMSSN; (2009) Research Focus: Researchers conduct innovative targeted lung cancer trials. SLMS Newsletter September 2009 (5) pp. 8-9.

V

Valle, JW; Wasan, H; Johnson, P; Jones, E; Dixon, L; Swindell, R; Baka, S; ... Bridgewater, J; + view all (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01. British Journal of Cancer , 101 (4) pp. 621-627.

Valle, JW; Wasan, HS; Palmer, DD; Cunningham, D; Anthoney, DA; Maraveyas, A; Hughes, SK; ... Bridgewater, JA; + view all (2009) Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol , 27 (15_suppl) 4503-.

Vassileva, V; (2009) Chemotherapy: Predictors of chemotherapy response in advanced CRC. Nature Reviews Clinical Oncology , 6 (5) 245-. 10.1038/nrclinonc.2009.31.

Vassileva, V; (2009) Hematology: Early markers for leukemia. Nature Reviews Clinical Oncology , 6 (5) 245-. 10.1038/nrclinonc.2009.34.

W

Wardley, A; McCaffrey, J; Crown, J; Stein, R; Malik, Z; Rea, D; Barrett-Lee, P; (2009) Preliminary Phase II Data Suggest That Entinostat (SNDX275), a Class 1 Selective Histone Deacetylase Inhibitor (HDACi), May Resensitize Breast Cancer Patients Progressing on Aromataste Inhibitor (AI) Therapy to Their AI Therapy. In: (pp. p. 6111).

Wetterskog, D; Moshiri, A; Ozaki, T; Uramoto, H; Nakagawara, A; Funa, K; (2009) Dysregulation of Platelet-Derived Growth Factor beta-Receptor Expression by Delta Np73 in Neuroblastoma. MOLECULAR CANCER RESEARCH , 7 (12) pp. 2031-2039. 10.1158/1541-7786.MCR-08-0501.

Whelan, J; (2009) Managing sarcomas in teenagers and young adults. In: EJC SUPPLEMENTS. (pp. 82 - 82). PERGAMON-ELSEVIER SCIENCE LTD

Windsor, R; Strauss, S; Seddon, B; Michelagnoli, M; Labrum, R; Wood, N; Whelan, ; (2009) A pilot pharmacogenomic study of the influence of cytotoxic target and metabolising gene polymorphisms on toxicity and response in osteosarcoma. In:

Y

Yovine, A; Casali, P; G, RF; Vermorken, J; Demetri, G; Whelan, JS; Almorin, E; ... Schoffski, P; + view all (2009) Trabectidin 3 hour infusion every 3 weeks in pre-treated advanced sarcoma patients: acompassionate use administration experience. In: (pp. 597-).

This list was generated on Sun Jun 17 01:46:42 2018 BST.